Revenue: As of FY2025 Q1, the actual value is USD 398.83 K.EPS: As of FY2025 Q1, the actual value is USD -0.029.EBIT: As of FY2025 Q1, the actual value is USD -720.89 K.<h3>Direct Sales</h3><ul><li>Revenue: $20,631 for the three months ended March 31, 2025, compared to $165,749 in the same period of 2024, representing a decrease of $145,118 or 88%.</li><li>Cost of Sales: $5,768 for 2025, compared with $19,708 for 2024, representing a decrease of $13,940 or 71%.</li><li>Operating Expenses: $188,568 for 2025, compared to $372,056 for 2024.</li><li>Loss from Operations: - $173,705 for 2025, compared to - $226,015 for 2024.</li></ul><h3>Pharmacy</h3><ul><li>Revenue: $35,966 for the three months ended March 31, 2025, compared to $241,118 in the same period of 2024, representing a decrease of $205,152 or 85%.</li><li>Cost of Sales: $24,051 for 2025, compared with $80,174 for 2024, representing a decrease of $56,123 or 70%.</li><li>Operating Expenses: $84,139 for 2025, compared to $110,870 for 2024.</li><li>Loss from Operations: - $72,224 for 2025, compared to $50,074 for 2024.</li></ul><h3>Hotel</h3><ul><li>Revenue: $80,706 for the three months ended March 31, 2025, compared to $154,465 for the same period of 2024, representing a decrease of $73,759 or 48%.</li><li>Operating Costs: $270,819 for 2025, compared to $461,079 for 2024, representing a decrease of $190,260 or 41%.</li><li>Operating Expenses: $60,769 for 2025, compared to $71,877 for 2024.</li><li>Loss from Operations: - $250,882 for 2025, compared to - $378,491 for 2024.</li></ul><h3>Manufacture and Sale</h3><ul><li>Revenue: $261,528 for the three months ended March 31, 2025, compared to $290,227 for the same period of 2024, representing a decrease of $28,699 or 10%.</li><li>Cost of Sales: $283,181 for 2025, compared with $227,929 for 2024, representing an increase of $55,252 or 24%.</li><li>Operating Expenses: $164,021 for 2025, compared to $129,112 for 2024.</li><li>Loss from Operations: - $185,674 for 2025, compared to - $66,814 for 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $675,948 for the three months ended March 31, 2025, compared to - $461,451 for 2024.</li><li>Net Cash Used in Investing Activities: $0 for 2025, compared to - $41,053 for 2024.</li><li>Net Cash Provided by Financing Activities: $676,398 for 2025, compared to $383,802 for 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to gain positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products, and raise cash through loans from related parties and potential equity offerings.</li><li>Non-Core Business: The company intends to explore opportunities in the healthcare market in China, including expanding its product line, acquiring additional pharmacies, and operating nursing homes and clinics.</li></ul>

AiXin Life International, Inc. | 10-Q: FY2025 Q1 Revenue: USD 398.83 K